298: A dilemma in ALS, the first MASH drug, & why gene therapy is hard
The Readout Loud - Un pódcast de STAT - Jueves
Categorías:
Bioethicist Holly Fernandez Lynch joins us to discuss the case of Amylyx Pharmaceuticals’ treatment for ALS and what its failure means for drug development. We also discuss the latest news in the life sciences, including a tepid reception for gene therapies, the future of CAR-T cancer treatment, and the first approved medicine for a prevalent liver disease.
